Edition:
United States

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

14.50USD
3:16pm EST
Change (% chg)

$0.12 (+0.83%)
Prev Close
$14.38
Open
$14.47
Day's High
$15.05
Day's Low
$14.47
Volume
19,126
Avg. Vol
--
52-wk High
$15.40
52-wk Low
$12.55

Summary

Name Age Since Current Position

Gerald Chan

66 2016 Chairman of the Board

Cedric Francois

44 2016 President, Chief Executive Officer, Co-Founder, Director

Pascal Deschatelets

45 2016 Co-Founder, Chief Operating Officer

Alec Machiels

43 2016 Co-Founder, Director

Daniel Geffken

2015 Interim Chief Financial Officer

Nicole Perry

51 2016 Vice President - Finance

David Watson

43 2014 General Counsel, Vice President of Corporate Development

Federico Grossi

42 2014 Vice President - Clinical Development

Sinclair Dunlop

44 2016 Director

Stephanie OBrien

58 2016 Director

Biographies

Name Description

Gerald Chan

Dr. Gerald Chan Ph.D. is Chairman of the Board Independent of the company. Chan is a venture capitalist whose work focuses on start-up biotechnology companies founded on novel science. He sits on the boards of several biotech companies including Aduro, Synchroneuron, Matrivax and Stealth Peptides. After completing his doctoral and post-doctoral training at Harvard University, he co-founded the Morningside Group, an investment firm with venture, private equity and property investments that maintains a strong commitment to social responsibility. Gerald is a director of the Morningside Foundation whose donations lead to the founding of the Morningside College of the Chinese University of Hong Kong and to the naming of the Harvard School of Public Health after his late father, T.H. Chan. Gerald remains closely associated with the School of Public Health where he is a Distinguished Visiting Fellow and a member of the Board of Dean’s Advisors. Gerald holds an honorary fellowship at Wolfson College of Oxford University and an honorary Doctor of Social Science degree from the Chinese University of Hong Kong.

Cedric Francois

Dr. Cedric Francois M.D. Ph.D., is Co-Founder, President, Chief Executive Officer, Director of the company. Dr. Francois is a co-founder of our company and has served as a member of our board of directors and as our President and Chief Executive Officer since September 2009. Prior to co-founding our company, Dr. Francois co-founded Potentia Pharmaceuticals, Inc., or Potentia, a private biotechnology company. Dr. Francois has served as President and Chief Executive Officer at Potentia since 2001. Dr. Francois received his M.D. from the University of Leuven in Belgium and his Ph.D. in physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Dr. Francois was a member of the research team that performed the first successful hand transplantation and of the Louisville Face Transplant Team, whose work supported hand transplantation in Lyon, France in 2005.

Pascal Deschatelets

Dr. Pascal Deschatelets Ph.D. is Co-Founder, Chief Operating Officer of the company. Dr. Deschatelets co-founded Apellis Pharmaceuticals in November 2009 and joined as its Chief Operating Officer. Prior to founding Apellis, Dr. Deschatelets co-founded Potentia Pharmaceuticals, and was its Chief Operating Officer when the company signed a licensing agreement with Alcon in 2009 for Potentia’s ocular drug development program. Apellis acquired all of the assets of Potentia in a transaction that closed in September 2015. Dr. Deschatelets has been engaged in state-of-the-art research in the areas of surface chemistry and organic synthesis for the last 25 years, and was a co-founder of Syntetica Fine Chemicals, a custom chemical synthesis company supporting the pharmaceutical industry. He has extensive experience in nanobiotechnology and in the synthesis of organic molecules and bioconjugates. Dr. Deschatelets received his Ph.D. in organic chemistry from the University of Montreal and his post-doctoral training in the laboratory of Dr. George Whitesides at Harvard University.

Alec Machiels

Mr. Alec Machiels is Co-Founder and Director of the Company. Machiels is a Partner at Pegasus Capital Advisors, L.P., a private equity fund manager. Mr. Machiels is a member of the firm’s Executive and Investment Committees. He has over 15 years of private equity investing and investment banking experience. Previously, Mr. Machiels was a Financial Analyst in the Financial Services Group at Goldman Sachs International in London and in the Private Equity Group at Goldman Sachs and Co. in New York. Investments in which he has been highly involved in include Pure Biofuels, Molycorp Minerals, Traxys, Slipstream Communications, Coffeyville Resources and Merisant Company. He also co-founded and serves as a board member of Potentia Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc. which respectively have drugs in development to treat macular degeneration and rare diseases and COPD. He also served as a member of the Board of Trustees of the American Federation of Arts where he chaired the endowment committee. Mr. Machiels is a graduate of Harvard Business School, KU Leuven Law School in Belgium and Konstanz University in Germany.

Daniel Geffken

Mr. Daniel E. Geffken CPA is Interim Chief Financial Officer of the company. Geffken has served as our Interim Chief Financial Officer since August 2015. Mr. Geffken is a founder and managing director at Danforth Advisors, LLC, a management consulting firm, where he has served since 2011. Previously, he served as chief operating officer of Seaside Therapeutics, Inc., a biotechnology company focused on neurodevelopmental disorders, from 2009 to 2011. In addition, prior to Seaside Therapeutics, Mr. Geffken previously served as chief operating officer or chief financial officer of several publicly traded and privately held companies, including Transkaryotic Therapies, Inc. and CytoTherapeutics, Inc. and as a principal of Signal Capital, Inc., a private equity firm. Mr. Geffken received his M.B.A from the Harvard Business School and his B.S. in economics from The Wharton School, University of Pennsylvania.

Nicole Perry

Ms. Nicole D. Perry is Vice President - Finance of the company. Ms. Perry has served as our Vice President of Finance since April 2015. From April 2015 to June 2015, Ms. Perry also served as Vice President of Finance at Revon Systems, LLC, or Revon, a private health care technology platform company. From August 2000 to April 2015, Ms. Perry worked as an independent consultant providing services to clients primarily in the areas of financial reporting, internal control compliance and as a liaison with external accountants, bankers and legal counsel. Prior to having her consulting practice, Ms. Perry spent nine years in public accounting, six years with PriceWaterhouseCoopers and three years with Deloitte. Ms. Perry was a part of the audit practice at both firms working on a variety of public and non-public clients. Ms. Perry is a Certified Public Accountant and received her a B.B.A. in accounting, with distinction, from the University of Oklahoma.

David Watson

Mr. David Watson J.D., is General Counsel, Vice President of Corporate Development of the company. Mr. Watson has been the Vice President of Corporate Development of Apellis Pharmaceuticals since 2014. Previously, Mr. Watson was a Member at Frost Brown Todd LLC, where his practice included equity finance, mergers & acquisitions and securities transactions. Mr. Watson is a graduate of Harvard College (B.A., magna cum laude, Phi Beta Kappa), Vanderbilt Law School (J.D.) and the University of Kentucky (M.A., mathematics).

Federico Grossi

Mr. Federico Grossi M.D., Ph.D., is Vice President - Clinical Development of the company. Dr. Grossi was Potentia Pharmaceuticals’ Clinical Research Director when he joined Apellis as the new company’s Clinical Research Director in 2010. Dr. Grossi received his medical degree from the University of Cordoba in Argentina and his Doctorate’s Degree in Physiology from the University of Louisville. Following his post graduate training in surgery, Dr. Grossi joined the Plastic Surgery Research Laboratory at the University of Louisville where he developed his expertise in microsurgery and composite tissue transplantation. He was a crucial member of the Louisville Face Transplant Team, which has published several manuscripts on the ethical and psychological aspect of face transplantation that are now considered hallmark publications in this field. He has also published numerous articles in the fields of ischemic preconditioning and composite tissue allotransplantation.

Sinclair Dunlop

Mr. Sinclair Dunlop is Director of the company. As Managing Partner of Epidarex, Mr. Dunlop leads the review and analysis of Epidarex investment candidates. A former international business and economics analyst with the Center for Strategic & International Studies in Washington, D.C., Mr. Dunlop has private equity and venture capital experience in Europe, the U.S. and Israel. Prior to founding Epidarex, Mr. Dunlop acted as the Director of New Business Ventures of MASA Life Science Ventures after a period as an Associate at New Vantage Group, manager of several early-stage venture capital funds in the Mid-Atlantic region. In May 2000, Mr. Dunlop received his M.B.A. from Columbia Business School where he was the R.C. Kopf British-American Fellow in international business. He also holds an M.A. with Honors in Political Economy from the University of Glasgow and an M.A. in International Relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. He is a St. Andrews Society of New York Scholar.

Stephanie OBrien

Ms. Stephanie Monaghan OBrien J.D. is Director of the company. Ms. O’Brien represents Morningside Ventures and has extensive experience working with venture-backed companies focused on novel science. She focuses on early-stage companies, working with CEOs on building the management team and developing business plans. She has served on numerous private company boards, including Aduro Biotech, Inc., ViOptiox, Inc., I-Behavior, Inc., Natural Polymer International Corp., Serica Technology, Inc., and BiddingForGood, Inc. She received her A.B., cum laude, from Harvard College and her J.D. from New York University School of Law. Prior to attending law school, Stephanie worked for Chase Manhattan Bank, N.A, where she completed the loan officer credit training program and then worked in international portfolio analysis. After law school, Stephanie spent nine years as a corporate lawyer with Hale and Dorr in the Boston and Washington, D.C. offices, working primarily with venture capital finance and start-up companies.